“We have been taking new policy steps at the FDA to support downward pressure on drug prices by helping to clear a path for more efficient generic development,” says FDA Commissioner Scott Gottlieb, M.D.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Administratorhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAdministrator2019-02-15 08:37:082019-02-15 13:42:05Statement from FDA Commissioner Scott Gottlieb, M.D., on new policy to improve access and foster price competition for drugs that face inadequate generic competition
